Preventive Medicine Center, China Academy of Traditional Chinese Medicine Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
China Science and Technology Development Center for Chinese Medicine, State Administration of Traditional Chinese Medicine of The Peoples Republic of China, Beijing, China.
Medicine (Baltimore). 2024 May 24;103(21):e38354. doi: 10.1097/MD.0000000000038354.
The aim of this study is to examine the impact of the Orlistat on glucose levels and glucose tolerance in individuals with prediabetes, as well as assess its efficacy and safety in preventing the progression to diabetes.
For achieving the appropriate randomized controlled trials, we enrolled the public datas from the following electronic databases: The Cochrane library, Embase, China National Knowledge Infrastructure, VIP, Wan-Fang, and China Biology Medicine disc. The article focused on the orlistat intervention of glucose tolerance and glycemic status in prediabetic patients. We restricted the publication time from the creation to May 2023.
Six subjects were included in the study, with a total of 1076 participants (532 in the control group vs 544 in the experimental group). The results indicated that the orlistat can reduce the fasting blood glucose [relative risk (RR) = -2.18, 95% confidence intervals (CI) (-2.471, -1.886)], as well as the 2 hour postprandial blood glucose [RR = -1.497, 95% CI (-1.811, -1.183)]. Furthermore, it can prevent the impaired glucose tolerance patients to type 2 diabetes mellitus [RR = 0.605, 95% CI (0.462, 0.791)], and reversal the impaired glucose tolerance [RR = 2.092, 95% CI (1.249, 3.503)].
In prediabetic people, the orlistat can control weight, reduce the fasting blood glucose and the 2 hour postprandial blood glucose, and then delay the progression of diabetes. However, due to the quantitative restrictions, additional high-quality study needs to be conducted to improve the reliability of the results.
本研究旨在探讨奥利司他对糖尿病前期个体血糖水平和葡萄糖耐量的影响，并评估其预防糖尿病进展的疗效和安全性。
为了进行适当的随机对照试验，我们从以下电子数据库中纳入了公共数据：Cochrane 图书馆、Embase、中国知网、维普、万方和中国生物医学文献数据库。文章重点关注奥利司他对糖尿病前期患者葡萄糖耐量和血糖状态的干预作用。我们将发表时间限制在从创建到 2023 年 5 月。
共有 6 项研究纳入 1076 名参与者（对照组 532 名，实验组 544 名）。结果表明，奥利司他可以降低空腹血糖[相对风险（RR）=-2.18，95%置信区间（CI）（-2.471，-1.886）]和餐后 2 小时血糖[RR=-1.497，95% CI（-1.811，-1.183）]。此外，它可以预防糖耐量受损患者发展为 2 型糖尿病[RR=0.605，95% CI（0.462，0.791）]，并逆转糖耐量受损[RR=2.092，95% CI（1.249，3.503）]。
在糖尿病前期人群中，奥利司他可以控制体重，降低空腹血糖和餐后 2 小时血糖，从而延缓糖尿病的进展。然而，由于定量限制，需要开展更多高质量的研究以提高结果的可靠性。
